Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease
By R. Cooper-DeHoff, Y. Gong, E. Handberg, A. Bavry, S. Denardo, G. Bakris, C. Pepine. Journal of the American Medical Association (JAMA), 2010
668 citations recorded by the source corpus.
Context Hypertension guidelines advocate treating systolic blood pressure (BP) to less than 130 mm Hg for patients with diabetes mellitus; however, data are lacking for the growing population who also have coronary artery disease (CAD). Objective To determine the association of systolic BP control achieved and adverse cardiovascular outcomes in a cohort of patients with diabetes and CAD. Design, Setting, and Patients Observational subgroup analysis of 6400 of the 22 576 participants in the International Verapamil SR-Trandolapril Study (INVEST). For this analysis, participants were at least 50 years old and had diabetes and CAD. Participants were recruited between September 1997 and December 2000 from 862 sites in 14 countries and were followed up through March 2003 with an extended follow-up through August 2008 through the National Death Index for US participants. Intervention Patients received first-line treatment of either a calcium antagonist or β-blocker followed by angiotensin-converting enzyme inhibitor, a diuretic, or both to achieve systolic BP of less than 130 and diastolic BP of less than 85 mm Hg. Patients were categorized as having tight control if they could maintain their systolic BP at less than 130 mm Hg; usual control if it ranged from 130 mm Hg to less than 140 mm Hg; and uncontrolled if it was 140 mm Hg or higher. Main Outcome Measures Adverse cardiovascular outcomes, including the primary outcomes which was the first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Results During 16 893 patient-years of follow-up, 286 patients (12.7%) who maintained tight control, 249 (12.6%) who had usual control, and 431 (19.8%) who had uncontrolled systolic BP experienced a primary outcome event. Patients in the usual-control group had a cardiovascular event rate of 12.6% vs a 19.8% event rate for those in the uncontrolled group (adjusted hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.25–1.71; P<.001). However, little difference existed between those with usual control and those with tight control. Their respective event rates were 12.6% vs 12.7% (adjusted HR, 1.11; 95% CI, 0.93–1.32; P=.24). The all-cause mortality rate was 11.0% in the tight-control group vs 10.2% in the usual-control group (adjusted HR, 1.20; 95% CI, 0.99–1.45; P=.06); however, when extended follow-up was included, risk of all-cause mortality was 22.8% in the tight control vs 21.8% in the usual control group (adjusted HR, 1.15; 95% CI, 1.01–1.32; P=.04). Conclusion Tight control of systolic BP among patients with diabetes and CAD was not associated with improved cardiovascular outcomes compared with usual control.
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/00ca040d1f7d9503189f1d1579d3ad2b8ecc1467
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Standards of Medical Care in Diabetes—2012 (2011, background): “A post hoc analysis of blood pressure control in 6,400 patients with diabetes and CAD enrolled in the International Verapamil/Trandolapril Study (INVEST) demonstrated that “tight control” (,130 mmHg) was not associated with improved cardiovascular outcomes compared with “usual care” (130–140 mmHg) (”
- Standards of Medical Care in Diabetes—2013 (2012, background): “blood pressure,130 mmHg) was not associated with improved cardiovascular outcomes compared with “usual care” (achieved systolic blood pressure 130– 140 mmHg) (260).”
- Diabetes in Older Adults (2012, neutral): “A post hoc analysis of the cohort of participants with diabetes in the International Verapamil SRTrandolapril Study (INVEST), whose mean age was ;65 years, showed that achieved SBP under 130 mmHg was not associated with improved cardiovascular outcomes compared with SBP under 140 mmHg (47).”
- ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “a nationwide register-based observational study in Sweden, which suggest that benefits do not increase below 130 mmHg.(326,511,512) The case of the diabetic patient with increased urinary protein excre-”
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Page 38 of 71 Recommend early revascularization for cardiogenic shock due to cardiac pump failure I B (291, 293, 294) DM Recommend medical treatment and decisions for testing and revascularization similar to those for patients without DM I A (173, 176, 295) Post–CABG Recommend GDMT antiplatelet and ”